Document:

Blueprint

Exhibit
10.34

 

 

ADGERO BIOPHARMACEUTICALS HOLDINGS, INC.

 

4365 US 1 South, STE 211

 Princeton, NJ 08540

 

 

WARRANT AGENT AGREEMENT

 

This
Warrant Agent Agreement, dated as of August 14, 2017 (the
“Agreement”), is entered into by and among Aegis
Capital Corp. (the “Warrant Agent”) and Adgero
Biopharmaceuticals Holdings, Inc.
(“Adgero”).

 

WITNESSETH:

 

WHEREAS, Adgero has
offered to certain of its warrant holders, subject to the terms and
conditions set forth in an “Offer to Exercise Warrants to
Purchase Common Stock of Adgero” dated as of the date of this
letter (the “Offer to Exercise”), the opportunity to
exercise, upon the terms set forth therein, warrants to purchase an
aggregate of 2,309,317 shares of Adgero’s common
stock, par value $0.0001 per share (the “Common Stock”)
at an exercise price of $5.00 per share, that were issued to (i)
investors in certain private placement transactions effectuated by
the Company in 2016 and 2017 (“Investor Warrants”),
(ii) shareholders and debt holders of the Company’s
wholly-owned subsidiary, Adgero Biopharmaceuticals, Inc.
(“Adgero Subsidiary”) in connection with the merger of
Adgero Subsidiary and the Company (“Merger Warrants”
and collectively with the Investor Warrants, the
“Warrants”);

 

WHEREAS, pursuant
to the Offer to Exercise, holders of the Warrants will be given the
opportunity to: (i) exercise the Warrants, at the stated exercise
price of $5.00 per share of Common Stock in cash; provided,
however, that such holders may only exercise the Warrants for up to
fifty percent (50%) of the shares of Common Stock underlying such
Warrants (the “Warrant Shares”) (an
“Exercise”), and (ii) for each Warrant Share issued
pursuant to an Exercise receive an additional Warrant Share
underlying the Warrant in exchange for the cancellation of the
right to exercise the Warrant with respect to such additional
Warrant Share, subject to the terms and conditions set forth in the
Offer to Exercise;

 

WHEREAS, the terms
of the Warrants held by holders who do not elect to participate in
the Offer to Exercise will retain in all respects their original
terms and provisions;

 

WHEREAS, Adgero
will cause certain offering materials describing, among other
things, the Offer to Exercise and other related materials relating
to the these matters (collectively, the “Offering
Materials”) to be circulated to holders of the
Warrants.

 

WHEREAS, Adgero
desires to engage the Warrant Agent pursuant to the terms of this
Agreement, and the Warrant Agent is willing to be so engaged, to
solicit the holders of the Warrants to participate in the Offer to
Exercise and to exercise their Warrants.

 

 

1

 

 

NOW,
THEREFORE, in consideration of the mutual promises hereinafter set
forth, the parties hereto agree as follows:

 

1. Engagement. Adgero hereby engages and
appoints the Warrant Agent as, and the Warrant Agent hereby agrees
to serve as, the exclusive Warrant Agent for Adgero in connection
with the Offer to Exercise. Warrant Agent shall, consistent with
its obligations under the Securities Act, the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and the
applicable rules and regulations of the SEC thereunder, the rules
and regulations of Financial Industry Regulatory Authority, Inc.,
and the applicable state securities laws and regulations, use its
reasonable commercial efforts to maximize the number of holders of
Warrants who elect to participate in the Offer to Exercise and
exercise their Warrants, including appropriate communications with
the record owners and beneficial owners of the Warrants, as well as
with said owners’ brokers, agents or other
representatives.

 

2. Offering Materials. Adgero shall cause
copies of the Offering Materials relating to the Offer to Exercise
to be delivered to each Warrant holder, and the Warrant Agent shall
have no responsibility in this regard. The Warrant Agent is not
authorized to furnish to holders of Warrants any information other
than that contained in the Offering Materials or in such other
material as may be provided by Adgero to holders of the Warrants.
The Warrant Agent will be supplied without charge with a reasonable
number of Offering Materials.

 

3. Offer to Exercise Acceptance Procedures.
The Offering Materials shall set forth the procedure for holders of
Warrants to participate in the Offer to Exercise and to exercise
their Warrants.

 

4. Compensation.

 

A. Fee. Subject to the valid participation
in the Offer to Exercise and the exercise of the Warrants by a
holder of a Warrant (including any transferees), the Warrant Agent
is entitled to receive from Adgero a fee (the “Solicitation
Fee”) equal to five percent (5%) of the cash Adgero receives
for each and every Exercise of a Warrant.

 

B. Expenses. Whether or not the
transactions contemplated hereunder are consummated or this
Agreement is terminated, Adgero agrees to reimburse the Warrant
Agent for any and all of its reasonable out-of-pocket expenses,
upon review of a detailed invoice for such reasonable out-of-pocket
expenses, including fees and disbursements of its counsel incurred
by the Warrant Agent in connection with this Agreement, up to the
sum of $35,000 (the “Expense Allowance”).
Notwithstanding the foregoing, the Expense Allowance otherwise
payable to the Warrant Agent shall be offset by the $15,000 Adgero
advances to legal counsel for the Warrant Agent upon the execution
of this Agreement.

 

C. Timing of Payment. Within ten (10)
business days after the expiration date of the Offer to Exercise,
Adgero will deliver a notice to the Warrant Agent setting forth the
number of Warrants which have been properly completed for Exercise
by Holders of the Warrants and accepted by Adgero, together with
payment of the Solicitation Fee and Expense Allowance (provided any
required invoices have been provided Adgero as set forth in Section
4.B above) and any documentation reasonably requested by the
Warrant Agent.

 

 

2

 

 

5. Inspection of Records. During the period
of the Offer to Exercise and for thirty (30) days thereafter, the
Warrant Agent may, at any time during business hours, examine the
records of Adgero which relates to the Offer to Exercise.
Notwithstanding the foregoing, the Warrant Agent agrees not to use
any confidential information concerning Adgero provided to the
Warrant Agent by Adgero for any purposes other than those
contemplated under this Agreement.

 

6. Termination. The term of this Agreement
shall be for the shorter of (i) six (6) months from and after the
date first above written or (ii) the completion of the Offer to
Exercise (the “Term”). Notwithstanding anything to the
contrary contained herein, the obligations of Adgero to the Warrant
Agent set forth in Sections 4 and 7 will survive any expiration or
termination of this Agreement.

 

7. Indemnification. In connection with
Adgero’s engagement of Warrant Agent, Adgero hereby agrees to
indemnify and hold harmless Warrant Agent and its affiliates, and
the respective directors, officers, shareholders, agents and
employees of any of the foregoing, as well as each person who
controls the Warrant Agent within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act (collectively the
“Indemnified Persons”), from and against any and all
claims, actions, suits, proceedings (including those of
shareholders), damages, liabilities and expenses incurred by any of
them (including the reasonable fees and expenses of counsel),
(collectively a “Claim”), including costs of
investigation or inquiry, which are (A) related to or arise out of
(i) any actions taken or omitted to be taken (including any untrue
statements made or any statements omitted to be made) by Adgero, or
(ii) any actions taken or omitted to be taken by any Indemnified
Person in connection with Adgero’ engagement of the Warrant
Agent, or (B) otherwise relate to or arise out of Warrant
Agent’s activities on Adgero’ behalf under Warrant
Agent’s engagement hereunder, and Adgero shall reimburse any
Indemnified Person for all expenses (including the reasonable fees
and expenses of counsel) incurred by such Indemnified Person in
connection with investigating, preparing or defending any such
claim, action, suit or proceeding, whether or not in connection
with pending or threatened litigation in which any Indemnified
Person is a party. Adgero will not, however, be responsible for any
Claim, which is finally judicially determined to have resulted from
the gross negligence or willful misconduct of any person seeking
indemnification for such Claim. Adgero further agrees that no
Indemnified Person shall have any liability to Adgero for or in
connection with Adgero’ engagement of Warrant Agent hereunder
except for any Claim incurred by Adgero as a result of such
Indemnified Person’s gross negligence or willful misconduct
(and in no event shall any such liability exceed, in the aggregate
for all Indemnified Persons, the amount of the Solicitation Fee
actually received by the Warrant Agent).

 

Adgero
further agrees that it will not, without the prior written consent
of Warrant Agent, settle, compromise or consent to the entry of any
judgment in any pending or threatened Claim in respect of which
indemnification may be sought hereunder (whether or not any
Indemnified Person is an actual or potential party to such Claim),
unless such settlement, compromise or consent includes an
unconditional, irrevocable release of each Indemnified Person from
any and all liability arising out of such Claim.

 

 

3

 

 

Promptly upon
receipt by an Indemnified Person of notice of any complaint or the
assertion or institution of any Claim with respect to which
indemnification is being sought hereunder, such Indemnified Person
shall notify Adgero in writing of such complaint or of such
assertion or institution but failure to so notify Adgero shall not
relieve Adgero from any obligation it may have hereunder, except
and only to the extent such failure results in the forfeiture by
Adgero of substantial rights and defenses. If Adgero so elects or
is requested by such Indemnified Person, Adgero will assume the
defense of such Claim, including the employment of counsel
reasonably satisfactory to such Indemnified Person and the payment
of the fees and expenses of such counsel. In the event, however,
that legal counsel to such Indemnified Person reasonably determines
that having common counsel would present such counsel with a
conflict of interest or if the defendant in, or target of, any such
Claim, includes an Indemnified Person and Adgero, and legal counsel
to such Indemnified Person reasonably concludes that there may be
legal defenses available to it or other Indemnified Persons
different from or in addition to those available to Adgero, then
such Indemnified Person may employ its own separate counsel to
represent or defend him, her or it in any such Claim and Adgero
shall pay the reasonable fees and expenses of such counsel.
Notwithstanding anything herein to the contrary, if Adgero fails
timely or diligently to defend, contest, or otherwise protect
against any Claim, the relevant Indemnified Party shall have the
right, but not the obligation, to defend, contest, compromise,
settle, assert crossclaims, or counterclaims or otherwise protect
against the same, and shall be fully indemnified by Adgero
therefor, including without limitation, for the reasonable fees and
expenses of its counsel and all amounts paid as a result of such
Claim or the compromise or settlement thereof. In addition, with
respect to any Claim in which Adgero assumes the defense, the
Indemnified Person shall have the right to participate in such
Claim and to retain his, her or its own counsel therefor at his,
her or its own expense.

 

Adgero
agrees that if any indemnity sought by an Indemnified Person
hereunder is held by a court to be unavailable for any reason then
(whether or not Warrant Agent is the Indemnified Person), Adgero
and Warrant Agent shall contribute to the Claim for which such
indemnity is held unavailable in such proportion as is appropriate
to reflect the relative benefits to Adgero, on the one hand, and
Warrant Agent on the other, in connection with Warrant
Agent’s engagement referred to above, subject to the
limitation that in no event shall the amount of Warrant
Agent’s contribution to such Claim exceed the amount of the
Solicitation Fee actually received by Warrant Agent from Adgero
pursuant to Warrant Agent’s engagement.

 

Adgero’s
indemnity, reimbursement and contribution obligations under this
Agreement (a) shall be in addition to, and shall in no way limit or
otherwise adversely affect any rights that any Indemnified Party
may have at law or at equity and (b) shall be effective whether or
not Adgero is at fault in any way.

 

8. Notices. All notices and other
communications given or made pursuant hereto shall be in writing
and shall be deemed to have been duly given or made as of the date
delivered personally, or the date mailed if mailed by registered or
certified mail (postage prepaid, return receipt requested) to the
parties at the following addresses (or at such other address for a
party as shall be specified by like changes of address which shall
be effective upon receipt) or sent by facsimile transmission, with
confirmation received, if sent to

 

 

 

4

 

 

the
Warrant Agent, will be mailed, delivered or telefaxed and confirmed
to:

 

Aegis
Capital Corp.

810
Seventh Ave, 11th Floor

New
York, New York 10019

 

Attention: Adam K.
Stern, telefax number (646) 390-9122

 

with a
copy (which shall not constitute notice) to:

 

Littman
Krooks LLP

655
Third Avenue, 20th Floor

New
York, NY 10017

Attn:
Steven Uslaner, Esq.

telefax
number (212) 490-2990

 

if sent
to Adgero, will be mailed, delivered or telefaxed and confirmed
to:

 

Adgero
Biopharmaceuticals Holdings, Inc.

 

4365
US1 South, Ste. 211

Princeton, NJ
08540

Attn:
Frank G. Pilkiewicz, Ph.D., President & CEO

 

with a
copy (which shall not constitute notice) to:

 

Lowenstein Sandler
LLP

 

1251
Avenue of the Americas

New
York, NY 10020

Attn:
Steven M. Skolnick, Esq.

telefax
number (973) 597 2477

 

9. Supplements and Amendments. Any term or
provision of this Agreement may be waived at any time by the party
which is entitled to the benefits thereof, but only in a writing
signed by such party, and this Agreement may be amended or
supplemented at any time, but only by written agreement of Adgero
and the Warrant Agent. Any such waiver with respect to a failure to
observe any such provision shall not operate as a waiver of any
subsequent failure to observe such provision unless otherwise
expressly provided in such waiver.

 

10. Assignments. This Agreement may not be
assigned by any party without the express written approval of all
other parties.

 

11. Governing Law. This Agreement shall be
governed by and construed in accordance with the internal laws (and
not the laws pertaining to conflicts of laws) of the State of New
York. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York applicable to
agreements made and to be fully performed therein. Any disputes
which arise under this Agreement, even after the termination of
this Agreement, will be heard only in the state or federal courts
located in the County of New York, State of New York. The parties
hereto expressly agree to submit themselves to the jurisdiction of
the foregoing courts in the County of New York, State of New York.
The parties hereto expressly waive any rights they may have to
contest the jurisdiction, venue or authority of any court sitting
in the County and State of New York. In the event of the bringing
of any action, or suit by a party hereto against the other party
hereto, arising out of or relating to this Agreement, the party in
whose favor the final judgment or award shall be entered shall be
entitled to have and recover from the other party the costs and
expenses incurred in connection therewith, including its reasonable
attorneys’ fees. Any rights to trial by jury with respect to
any such action, proceeding or suit are hereby waived by Warrant
Agent and Adgero.

 

 

5

 

 

12. Benefits of this Agreement. Nothing in
this Agreement shall be construed to give any person or entity
other than Adgero and the Warrant Agent any legal or equitable
right, remedy or claim under this Agreement; and this Agreement
shall be for the sole and exclusive benefit of Adgero and the
Warrant Agent.

 

13. Descriptive Headings. The descriptive
headings of the sections of this Agreement are inserted for
convenience only and shall not control or affect the meanings or
construction of any of the provisions hereof.

 

14. Enforceability. If any of the provisions
of this Agreement are held to be void or unenforceable, all of the
other provisions shall nonetheless continue in full force and
effect.

 

15. Waiver. The waiver by any of the parties
hereto of a breach or alleged breach of the terms of this Agreement
by the other party shall not constitute a waiver of any other
breach or alleged breach.

 

16. Counterparts.
This Agreement may be executed in counterparts, each of
which shall be deemed an original, but all of which together shall
be deemed to be one and the same agreement. A signed copy of
this Agreement delivered by facsimile, e-mail or other
means of electronic transmission shall be deemed to have the same
legal effect as delivery of an original signed copy of
this Agreement.

 

17. Entire Agreement. This Agreement
supersedes all previous arrangements and agreements whether written
or oral, and comprises the entire agreement, between Adgero and the
Warrant Agent in respect of the subject matter hereof.

 

 

 

[Remainder
of Page Intentionally Left Blank]

 

 

 

 

6

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the day and year first above
written.

 

ADGERO
BIOPHARMACEUTICALS HOLDINGS, INC.

 

By:____/s/ Frank G. Pilkiewicz, Ph.D.
_

Name:                       

Frank G.
Pilkiewicz, Ph.D.

Title:                       

President &
Chief Executive Officer

 

Accepted and agreed
to this

14th
day of August, 2017:

 

 

AEGIS
CAPITAL CORP.

 

 

By:
___/s/ Adam K.
Stern___________

Name:                       

Adam K.
Stern

Title:                       

Head of Private
Equity Banking

 

 

 

[Signature Page to Warrant Engagement
Agreement]

 

7Blueprint

Exhibit
10.35

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (this
“Agreement”), dated as of
September 1, 2017 is by and between ADGERO BIOPHARMACEUTICALS
HOLDINGS, INC., a Delaware corporation (the “Company”) and Felix
Garzon (the “Employee”).

 

W I T N E S S E T
H:

 

WHEREAS, the Company desires to employ
the Employee as its Chief Medical Officer and the Employee desires
to accept such employment, on the terms and conditions set forth in
this Agreement; and

 

WHEREAS, the Company and the Employee
have mutually agreed that, as of the Start Date (as defined below),
this Agreement shall govern the terms of employment between the
Employee and the Company.

 

NOW, THEREFORE, in consideration of the
promises and the mutual covenants and agreements contained herein
and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto,
intending to be legally bound hereby, agree as
follows:

 

 ARTICLE
1

Employment;TERM
OF AGREEMENT

 

Section
1.1. Employment and Acceptance.
During the Term (as defined in Section 1.2), the Company shall
employ the Employee, and the Employee shall accept such employment
and serve the Company, in each case, subject to the terms and
conditions of this Agreement.

 

Section
1.2. Term. The employment
relationship hereunder shall be for the period (such period of the
employment relationship shall be referred to herein as the
“Term”)
commencing on September 1, 2017, or such earlier date as mutually
agreed to in writing by the Company and the Employee (the
“Start
Date”) and ending upon the termination of the
Employee’s employment hereunder by either party hereto
pursuant to the terms of Section 4.1, Section 4.2 or Section 4.3. In the event that
the Employee’s employment with the Company hereunder
terminates, the Company’s obligation to continue to pay,
after the Termination Date (as defined in Section 4.2(a)), Base Salary
(as defined in Section
3.1(a)), Annual Bonus (as defined in Section 3.1(b)) and other
unaccrued benefits shall terminate, except to the extent provided
for in ARTICLE
4.

 

 ARTICLE
2

TITLE; DUTIES
AND OBLIGATIONS; LOCATION

 

Section
2.1. Title. The Company shall employ
the Employee to render exclusive and full-time services to the
Company. The Employee shall serve in the capacity of Chief Medical
Officer.

 

Section
2.2. Duties. The Employee shall
report to the Company’s Chief Executive Officer (the
“CEO”)
and be subject to the lawful direction of the CEO. The Employee
agrees to perform to the best of his ability, experience and talent
those acts and duties, consistent with the position of Chief
Medical Officer as the CEO shall from time to time
direct.

 

 

1

 

 

Section
2.3. Compliance with Policies, etc.
During the Term, the Employee shall be bound by, and comply fully
with, all of the Company’s policies and procedures for
employees in place from time to time, including, but not limited
to, all terms and conditions set forth in the Company’s
employee handbook, compliance manual, codes of conduct and any
other memoranda and communications applicable to the Employee
pertaining to the policies, procedures, rules and regulations, as
currently in effect and as may be amended from time to time. These
policies and procedures include, among other things and without
limitation, the Employee’s obligations to comply with the
Company’s rules regarding confidential and proprietary
information and trade secrets.

 

Section
2.4. Time Commitment. During the
Term, the Employee shall use his best efforts to promote the
interests of the Company (including its subsidiaries and other
Affiliates) and shall devote all of his business time, ability and
attention to the performance of his duties for the Company. and
shall not, directly or indirectly, render any services to any other
person or organization, whether for compensation or otherwise,
except (with the Board of Director’s (the “Board”) prior written
consent, provided that the foregoing shall not prevent the Employee
from (i) participating in charitable, civic, educational,
professional, community or industry affairs, or (ii) managing the
Employee’s passive personal investments, so long as, in each
case, such activities individually or in the aggregate do not
materially interfere or conflict with the Employee’s duties
hereunder or create a potential business or fiduciary conflict (in
each case, as determined by the Board).

 

Section
2.5. Location. The Employee’s
principal place of business for the performance of his duties under
this Agreement shall be at the principal executive office of the
Company located at 4365 US Route 1 South, Suite 211, Princeton, New
Jersey 08540, as of the Start Date; provided, however the Employee
may be eligible to work remotely from time to time in the
discretion of the Company. The Employee shall travel as determined
necessary to perform his duties hereunder by the CEO.

 

 ARTICLE
3

COMPENSATION
AND BENEFITS; EXPENSES

 

Section
3.1. Compensation and Benefits. For
all services rendered by the Employee in any capacity during the
Term (including, without limitation, serving as an officer,
director or member of any committee of the Company or any of its
subsidiaries or other Affiliates), the Employee shall be
compensated as follows (subject, in each case, to the provisions of
ARTICLE 4
below):

 

(a)           Base
Salary. During the Term, the Company shall pay the Employee
a base salary (the “Base Salary”) at the
annualized rate of $320,000, which shall be subject to customary
withholdings and authorized deductions and be payable in equal
installments in accordance with the Company’s customary
payroll practices in place from time to time. The Employee’s
Base Salary and title shall be subject to, on an annual basis
beginning in January 2018, periodic review and adjustments as the
Board and/or the Compensation Committee of the Board (the
“Compensation
Committee”) shall in its/their discretion deem
appropriate.

 

 

2

 

 

 

 

(b)           Annual
Bonus. For each calendar year ending during the Term
(beginning with the calendar year ending December 31, 2017), the
Employee shall be eligible to receive an annual bonus (the
“Annual
Bonus”) with a target amount equal to thirty five
percent (35%) of the Base Salary earned by the Employee for such
calendar year (the “Target Annual Bonus”).
Notwithstanding the foregoing, for calendar year 2017, the Employee
will be eligible to receive an Annual Bonus, pro-rated for the
period between the Start Date and December 31, 2017. The actual
amount of each Annual Bonus will be based upon the level of
achievement of the Company’s corporate objectives and the
Employee’s individual objectives, in each case, as
established by the Board or the Compensation Committee (taking into
account the input of the CEO with respect to the establishment of
the Employee’s individual objectives) for the calendar year
with respect to which such Annual Bonus relates. The determination
of the level of achievement of the corporate objectives and the
Employee’s individual performance objectives for a year shall
be made by the Board or the Compensation Committee (taking into
account the input of the CEO with respect to the establishment of
the Employee’s individual objectives), in its reasonable
discretion. Each Annual Bonus for a calendar year, to the extent
earned, will be paid in a lump sum in the following calendar year,
within the first 75 days of such following year. The Annual Bonus
shall not be deemed earned until the date that it is paid.
Accordingly, in order for the Employee to receive an Annual Bonus,
the Employee must be actively employed by the Company at the time
of such payment.

 

(c)           Equity
Compensation. Subject to the terms of the Company’s
2016 Equity Incentive Plan (the “Plan”) and approval of
the Board or Compensation Committee, at the next regular meeting of
the Board or the Compensation Committee on or following the Start
Date, the Employee will be granted options to purchase up to 90,000
shares of the Company’s common stock, subject to shareholder
approval of an increase in the number of shares available under the
Plan, on the terms and conditions determined by the Board or the
Compensation Committee, with an exercise price of $5.00 per share
(provided that the Board or the Compensation Committee determines
that such exercise price represents no less than fair market value
per share on the date of grant in accordance with the Plan).
The shares subject to the
option shall vest in three (3) equal annual installments, beginning
on the first anniversary of the date of grant, and continuing on
each of the second and third anniversaries, provided that the
Employee remains employed by or remains a service provider to, the
Company through each applicable vesting date. During the Term,
subject to the terms and conditions established within the Plan or
any successor equity compensation plan as may be in place from time
to time and separate award agreements, the Employee also shall be
eligible to receive from time to time stock options, stock unit
awards, performance shares, performance units, incentive bonus
awards, other cash-based awards and/or other stock-based awards (as
permitted by the Plan), in amounts, if any, to be approved by the
Board or the Compensation Committee in its discretion.
Notwithstanding anything in the Plan to the contrary, if (i) the
Termination Date occurs at least six (6) months after the Start
Date and (ii) the Employee is terminated without Cause (as defined
in Section 4.1(b)) or resigns with Good Reason (as defined in
Section 4.1(c)) within twenty-four (24) months following a Change
in Control (as defined in Section 5.19), the Employee shall receive
accelerated vesting of all unvested options upon the Termination
Date and all of the Employee’s outstanding vested stock
options shall remain exercisable for a period of six (6) months,
measured from the Termination Date (but in no event later than the
expiration date of their term); provided, however, that in the event
stock options under the Plan are cancelled or otherwise terminated
pursuant to the Plan in connection with such Change in Control, the
Employee’s stock options may be cancelled or otherwise
terminated, as applicable, on terms no less favorable than those
provided to other similarly situated option holders. This
Section 3.1(c)
shall be deemed an amendment to each award agreement entered into
by the Employee evidencing a grant of stock options, whether
entered into prior to the Start Date or during the Term (but, in no
event shall this Section
3.1(c) be deemed an amendment to any award agreement entered
into after expiration of the Term).

 

 

3

 

 

(d)           Benefit
Plans. The Employee shall be entitled to participate in all
employee benefit plans and programs (excluding severance plans, if
any) generally made available by the Company to executives of the
Company, to the extent permissible under the general terms and
provisions of such plans or programs and in accordance with the
provisions thereof. The Company may amend, modify or rescind any
employee benefit plan or program and/or change employee
contribution amounts to benefit costs without notice in its
discretion.

 

(e)           Paid
Vacation. The Employee shall be entitled to paid vacation
days in accordance with the Company’s vacation policies in
effect from time to time for its executive team; provided, however, that the Employee
shall be entitled to no less than fifteen (15) paid vacation days
per calendar year during the Term.

 

Section
3.2. Expense
Reimbursement. The Company shall reimburse the Employee
during the Term, in accordance with the Company’s expense
reimbursement policies in place from time to time, for all
reasonable out-of-pocket business expenses incurred by the Employee
in the performance of his duties hereunder. In order to receive
such reimbursement, the Employee shall furnish to the Company
documentary evidence of each such expense in the form required to
comply with the Company’s policies in place from time to
time.

 

 ARTICLE
4

TERMINATION
OF EMPLOYMENT

 

Section
4.1.Termination Without
Cause or Resignation for Good Reason.

 

(a) The Company may
terminate the Employee’s employment hereunder at any time
without Cause (other than by reason of death or Disability) upon
sixty (60) days prior written notice to the Employee. Employee may
terminate his employment hereunder for Good Reason upon written
notice to the Company in accordance with the provisions set forth
in Section
4.1(c).

 

(b) As used in this
Agreement, “Cause” means: (i) a
material act, or act of fraud, committed by the Employee that is
intended to result in the Employee’s personal enrichment to
the detriment or at the expense of the Company or any of its
Affiliates; (ii) the Employee is convicted of a felony; (iii) gross
negligence or willful misconduct by the Employee, or failure by the
Employee to perform the duties or obligations reasonably assigned
to the Employee by the CEO (or the Board) from time to time, which
is not cured upon ten (10) days prior written notice (unless such
negligence, misconduct or failure is not susceptible to cure, as
determined in the reasonable discretion of the Board); or (iv) the
Employee violates the Covenants Agreement (as defined in
Section 5.1
below).

 

(c) As used in this
Agreement, “Good
Reason” means the occurrence of any of the following:
(1) a material breach by the Company of the terms of this
Agreement; (2) a material reduction in the Employee’s Base
Salary (other than pursuant to a reduction uniformly applicable to
all executives of the Company); or (3) a material diminution in the
Employee’s authority, duties or responsibilities;
provided,
however, that the
Employee must notify the Company within ninety (90) days of the
occurrence of any of the foregoing conditions that he considers it
to be a “Good Reason” condition and provide the Company
with at least thirty (30) days in which to cure the condition. If
the Employee fails to provide this notice and cure period prior to
his resignation, or resigns more than six (6) months after the
initial existence of the condition, his resignation will not be
deemed to be for “Good Reason.” It is an express
condition of this Agreement that an acquiring entity in a Change in
Control assume this Agreement; if this Agreement is not so assumed,
it shall constitute a material breach of the terms of the
Agreement.

 

 

4

 

 

(d) If the
Employee’s employment is terminated pursuant to Section 4.1(a), the Employee
shall, in full discharge of all of the Company’s obligations
to the Employee, be entitled to receive, and the Company’s
sole obligation to the Employee under this Agreement or otherwise
shall be to pay or provide to the Employee, the following
(collectively, the “Accrued Obligations”):

 

(i)                 the
Employee’s earned, but unpaid, Base Salary through the final
date of the Employee’s employment by the Company (the
“Termination
Date”), payable in accordance with the Company’s
standard payroll practices;

 

(ii)                 the
Employee’s accrued, but unused, vacation (in accordance with
the Company’s policies);

 

(iii)                 
expenses reimbursable under Section 3.2 above incurred on
or prior to the Termination Date but not yet reimbursed;
and

 

(iv)                 
any amounts or benefits that are vested amounts or vested benefits
or that the Employee is otherwise entitled to receive under any
Company plan, program, policy or practice (with the exception of
those, if any, relating to severance) on the Termination Date, in
accordance with such plan, program, policy, or
practice.

 

Section
4.2. Termination for
Cause; Voluntary Termination. The Company may terminate the
Employee’s employment hereunder at any time for Cause upon
written notice to the Employee. The Employee may voluntarily
terminate his employment hereunder at any time without Good Reason
upon sixty (60) days prior written notice to the Company; provided,
however, the Company reserves the right, upon written notice to the
Employee, to accept the Employee’s notice of resignation and
to accelerate such notice and make the Employee’s resignation
effective immediately, or on such other date prior to
Employee’s intended last day of work as the Company deems
appropriate. It is understood and agreed that the Company’s
election to accelerate Employee’s notice of resignation shall
not be deemed a termination by the Company without Cause for
purposes of Section 4.1 of this Agreement or otherwise or
constitute Good Reason (as defined in Section 4.1) for purposes of
Section 4.1 of this Agreement or otherwise. If the Employee’s
employment is terminated pursuant to Section 4.2, the Employee
shall, in full discharge of all of the Company’s obligations
to the Employee, be entitled to receive, and the Company’s
sole obligation under this Agreement or otherwise shall be to pay
or provide to the Employee, the Accrued Obligations.

 

Section
4.3. 

Termination Resulting from Death or
Disability.

 

(a)           As
the result of any Disability suffered by the Employee, the Company
may, upon five (5) days prior notice to the Employee, terminate the
Employee’s employment under this Agreement. The
Employee’s employment shall automatically terminate upon his
death.

 

(b) “Disability” means a
determination by the Company in accordance with applicable law that
as a result of a physical or mental injury or illness, the Employee
has been unable to perform the essential functions of his job with
or without reasonable accommodation for a period of (i) ninety (90)
consecutive days; or (ii) one hundred twenty (120) days during any
twelve (12) month period.

 

 

 

5

 

 

(c) If the
Employee’s employment is terminated pursuant to Section 4.3(a), the Employee or
the Employee’s estate, as the case may be, shall be entitled
to receive, and the Company’s sole obligation under this
Agreement or otherwise shall be to pay or provide to the Employee
or the Employee’s estate, as the case may be, the Accrued
Obligations.

 

Section
4.4. Removal from any
Boards and Position. If the Employee’s employment is
terminated for any reason under this Agreement, he shall be deemed
(without further action, deed or notice) to resign (i) if a member,
from the Board or board of directors (or similar governing body) of
any Affiliate of the Company or any other board to which he has
been appointed or nominated by or on behalf of the Company and (ii)
from all other positions with the Company or any subsidiary or
other Affiliate of the Company, including, but not limited to, as
an officer of the Company and any of its subsidiaries or other
Affiliates.

 

 ARTICLE
5

GENERAL
PROVISIONS

 

Section
5.1. Company
Non-Disclosure and Invention Assignment Agreement. The
Employee acknowledges and confirms that the Non-Disclosure and
Invention Assignment Agreement executed by the Employee in favor of
the Company in September, 2017 (“Covenants Agreement”),
the terms of which are incorporated herein by reference, remains in
full force and effect and binding upon the Employee. The Covenants
Agreement shall survive the termination of this Agreement and the
Employee’s employment by the Company for the applicable
period(s) set forth therein.

 

Section
5.2. Expenses. Each
of the Company and the Employee shall bear its/his own costs, fees
and expenses in connection with the negotiation, preparation and
execution of this Agreement.

 

Section
5.3. Entire
Agreement. This Agreement and the Covenants Agreement
contain the entire agreement of the parties hereto with respect to
the terms and conditions of the Employee’s employment during
the Term and activities following termination of this Agreement and
the Employee’s employment with the Company and supersede any
and all prior agreements and understandings, whether written or
oral, between the parties hereto with respect to the subject matter
of this Agreement or the Covenants Agreement. Each party hereto
acknowledges that no representations, inducements, promises or
agreements, whether oral or in writing, have been made by any
party, or on behalf of any party, which are not embodied herein or
in the Covenants Agreement. The Employee acknowledges and agrees
that the Company has fully satisfied, and has no further,
obligations to the Employee arising under, or relating to, any
other employment or consulting arrangement or understanding
(including, without limitation, any claims for compensation or
benefits of any kind) or otherwise. No agreement, promise or
statement not contained in this Agreement or the Covenants
Agreement shall be valid and binding, unless agreed to in writing
and signed by the parties sought to be bound thereby.

 

 

 

6

 

 

Section
5.4. No Other
Contracts. The Employee represents and warrants to the
Company that neither the execution and delivery of this Agreement
by the Employee nor the performance by the Employee of the
Employee’s obligations hereunder, shall constitute a default
under or a breach of the terms of any other agreement, contract or
other arrangement, whether written or oral, to which the Employee
is a party or by which the Employee is bound, nor shall the
execution and delivery of this Agreement by the Employee nor the
performance by the Employee of his duties and obligations hereunder
give rise to any claim or charge against either the Employee, the
Company or any Affiliate, based upon any other contract or other
arrangement, whether written or oral, to which the Employee is a
party or by which the Employee is bound. The Employee further
represents and warrants to the Company that he is not a party to or
subject to any restrictive covenants, legal restrictions or other
agreement, contract or arrangement, whether written or oral, in
favor of any entity or person which would in any way preclude,
inhibit, impair or limit the Employee’s ability to perform
his obligations under this Agreement or the Covenants Agreement,
including, but not limited to, non-competition agreements,
non-solicitation agreements or confidentiality agreements. The
Employee shall defend, indemnify and hold the Company harmless from
and against all claims, actions, losses, liabilities, damages,
costs and expenses (including reasonable attorney’s fees and
amounts paid in settlement in good faith) arising from or relating
to any breach of the representations and warranties made by the
Employee in this Section
5.4.

 

Section
5.5. Notices. Any
notice or other communication required or permitted hereunder shall
be in writing and shall be delivered personally or sent by
nationally recognized overnight courier service (with next business
day delivery requested). Any such notice or communication shall be
deemed given and effective, in the case of personal delivery, upon
receipt by the other party, and in the case of a courier service,
upon the next business day, after dispatch of the notice or
communication. Any such notice or communication shall be addressed
as follows:

 

If
to the Company, to:

 

Adgero
Biopharmaceuticals Holdings, Inc.

4365 US
Route 1 South

Suite
211

Princeton, NJ
08540

Attn:
Chief Executive Officer

 

With
a copy to:

 

Lowenstein Sandler
LLP

1251
Avenue of the Americas

New
York, New York 10020

Attn:
Michael J. Lerner, Esq.

 

If
to the Employee, to:

 

Felix
Garzon

54
Polifly Road

Hackensack, NJ
07601

 

With
a copy to:

 

                                 

___________________

____________________

 

 

7

 

 

Any
person named above may designate another address or fax number by
giving notice in accordance with this Section to the other persons
named above.

 

Section
5.6. Governing Law;
Jurisdiction. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of New Jersey,
without regard to principles of conflicts of law. Any and all
actions arising out of this Agreement or Employee’s
employment by Company or termination therefrom shall be brought and
heard in the state and federal courts of the State of New Jersey
and the parties hereto hereby irrevocably submit to the exclusive
jurisdiction of any such courts. THE COMPANY AND THE EMPLOYEE
HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY IN ANY ACTION
CONCERNING THIS AGREEMENT OR ANY AND ALL MATTERS ARISING DIRECTLY
OR INDIRECTLY HEREFROM AND REPRESENT THAT THEY HAVE CONSULTED WITH
COUNSEL OF THEIR CHOICE OR HAVE CHOSEN VOLUNTARILY NOT TO DO SO
SPECIFICALLY WITH RESPECT TO THIS WAIVER.

 

Section
5.7. Waiver. Either
party hereto may waive compliance by the other party with any
provision of this Agreement. The failure of a party to insist on
strict adherence to any term of this Agreement on any occasion
shall not be considered a waiver or deprive that party of the right
thereafter to insist upon strict adherence to that term or any
other term of this Agreement. No waiver of any provision shall be
construed as a waiver of any other provision. Any waiver must be in
writing.

 

Section
5.8. Severability.
If any one or more of the terms, provisions, covenants and
restrictions of this Agreement shall be determined by a court of
competent jurisdiction to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of
this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated and the parties will
attempt to agree upon a valid and enforceable provision which shall
be a reasonable substitute for such invalid and unenforceable
provision in light of the tenor of this Agreement, and, upon so
agreeing, shall incorporate such substitute provision in this
Agreement. In addition, if any one or more of the provisions
contained in this Agreement shall for any reason be determined by a
court of competent jurisdiction to be excessively broad as to
duration, geographical scope, activity or subject, it shall be
construed, by limiting or reducing it, so as to be enforceable to
the extent compatible with then applicable law.

 

Section
5.9. Counterparts.
This Agreement may be executed in any number of counterparts and
each such duplicate counterpart shall constitute an original, any
one of which may be introduced in evidence or used for any other
purpose without the production of its duplicate counterpart.
Moreover, notwithstanding that any of the parties did not execute
the same counterpart, each counterpart shall be deemed for all
purposes to be an original, and all such counterparts shall
constitute one and the same instrument, binding on all of the
parties hereto.

 

Section
5.10. Advice of
Counsel. This Agreement was prepared by Lowenstein Sandler
LLP in its capacity as legal counsel to the Company. Both parties
hereto acknowledge that they have had the opportunity to seek and
obtain the advice of counsel before entering into this Agreement
and have done so to the extent desired, and have fully read the
Agreement and understand the meaning and import of all the terms
hereof.

 

 

 

8

 

 

Section
5.11. Assignment.
This Agreement shall inure to the benefit of the Company and its
successors and assigns (including, without limitation, the
purchaser of all or substantially all of its assets) and shall be
binding upon the Company and its successors and assigns. This
Agreement is personal to the Employee, and the Employee shall not
assign or delegate his rights or duties under this Agreement, and
any such assignment or delegation shall be null and
void.

 

Section
5.12. Agreement to Take
Actions. Each party to this Agreement shall execute and
deliver such documents, certificates, agreements and other
instruments, and shall take all other actions, as may be reasonably
necessary or desirable in order to perform their or its obligations
under this Agreement.

 

Section
5.13. No
Attachment. Except as required by law, no right to receive
payments under this Agreement shall be subject to anticipation,
commutation, alienation, sale, assignment, encumbrance, charge,
pledge, or hypothecation or to execution, attachment, levy or
similar process or assignment by operation of law, and any attempt,
voluntary or involuntary, to effect any such action shall be null,
void and of no effect; provided, however, that nothing in this Section 5.13 shall preclude the
assumption of such rights by executors, administrators or other
legal representatives of the Employee or the Employee’s
estate and their assigning any rights hereunder to the person or
persons entitled thereto.

 

Section
5.14. Source of
Payment. Except as otherwise provided under the terms of any
applicable employee benefit plan, all payments provided for under
this Agreement shall be paid in cash from the general funds of
Company. The Company shall not be required to establish a special
or separate fund or other segregation of assets to assure such
payments, and, if the Company shall make any investments to aid it
in meeting its obligations hereunder, the Employee shall have no
right, title or interest whatever in or to any such investments
except as may otherwise be expressly provided in a separate written
instrument relating to such investments. Nothing contained in this
Agreement, and no action taken pursuant to its provisions, shall
create or be construed to create a trust of any kind, or a
fiduciary relationship, between the Company and the Employee or any
other person. To the extent that any person acquires a right to
receive payments from the Company hereunder, such right, without
prejudice to rights which employees may have, shall be no greater
than the right of an unsecured creditor of the Company. The
Employee shall not look to the owners of the Company for the
satisfaction of any obligations of the Company under this
Agreement.

 

Section
5.15. Tax
Withholding. The Company or other payor is authorized to
withhold from any benefit provided or payment due hereunder, the
amount of withholding taxes due any federal, state or local
authority in respect of such benefit or payment and to take such
other action as may be necessary in the opinion of the Board to
satisfy all obligations for the payment of such withholding taxes.
The Employee will be solely responsible for all taxes assessed
against his with respect to the compensation and benefits described
in this Agreement, other than typical employer-paid taxes such as
FICA, and the Company makes no representations as to the tax
treatment of such compensation and benefits.

 

 

 

9

 

 

Section
5.16. 409A
Compliance. All payments under this Agreement are intended
to comply with or be exempt from the requirements of Section 409A
of the Code and regulations promulgated thereunder
(“Section
409A”). As used in this Agreement, the
“Code”
means the Internal Revenue Code of 1986, as amended. To the extent
permitted under applicable regulations and/or other guidance of
general applicability issued pursuant to Section 409A, the Company
reserves the right to modify this Agreement to conform with any or
all relevant provisions regarding compensation and/or benefits so
that such compensation and benefits are exempt from the provisions
of 409A and/or otherwise comply with such provisions so as to avoid
the tax consequences set forth in Section 409A and to assure that
no payment or benefit shall be subject to an “additional
tax” under Section 409A. To the extent that any provision in
this Agreement is ambiguous as to its compliance with Section 409A,
or to the extent any provision in this Agreement must be modified
to comply with Section 409A, such provision shall be read in such a
manner so that no payment due to the Employee shall be subject to
an “additional tax” within the meaning of Section
409A(a)(1)(B) of the Code. If necessary to comply with the
restriction in Section 409A(a)(2)(B) of the Code concerning
payments to “specified employees,” any payment on
account of the Employee’s separation from service that would
otherwise be due hereunder within six (6) months after such
separation shall be delayed until the first business day of the
seventh month following the Termination Date and the first such
payment shall include the cumulative amount of any payments
(without interest) that would have been paid prior to such date if
not for such restriction. Each payment in a series of payments
hereunder shall be deemed to be a separate payment for purposes of
Section 409A. In no event may the Employee, directly or indirectly,
designate the calendar year of payment. All reimbursements provided
under this Agreement shall be made or provided in accordance with
the requirements of Section 409A, including, where applicable, the
requirement that (i) any reimbursement is for expenses incurred
during the Employee’s lifetime (or during a shorter period of
time specified in this Agreement), (ii) the amount of expenses
eligible for reimbursement during a calendar year may not affect
the expenses eligible for reimbursement in any other calendar year,
(iii) the reimbursement of an eligible expense will be made on or
before the last day of the calendar year following the year in
which the expense is incurred, and (iv) the right to reimbursement
is not subject to liquidation or exchange for another benefit.
Notwithstanding anything contained herein to the contrary, the
Employee shall not be considered to have terminated employment with
the Company for purposes of Section 4.1 unless the Employee
would be considered to have incurred a “termination of
employment” from the Company within the meaning of Treasury
Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall
the Company be liable for any additional tax, interest or penalty
that may be imposed on the Employee by Section 409A or damages for
failing to comply with Section 409A.

 

 

 

10

 

 

Section
5.17. 280G Modified
Cutback.

 

(a)          If
any payment, benefit or distribution of any type to or for the
benefit of the Employee, whether paid or payable, provided or to be
provided, or distributed or distributable pursuant to the terms of
this Agreement or otherwise (collectively, the “Parachute Payments”)
would subject the Employee to the excise tax imposed under Section
4999 of the Code (the “Excise Tax”), the
Parachute Payments shall be reduced so that the maximum amount of
the Parachute Payments (after reduction) shall be one dollar
($1.00) less than the amount which would cause the Parachute
Payments to be subject to the Excise Tax; provided that the
Parachute Payments shall only be reduced to the extent the
after-tax value of amounts received by the Employee after
application of the above reduction would exceed the after-tax value
of the amounts received without application of such reduction. For
this purpose, the after-tax value of an amount shall be determined
taking into account all federal, state, and local income,
employment and excise taxes applicable to such amount. Unless the
Employee shall have given prior written notice to the Company to
effectuate a reduction in the Parachute Payments if such a
reduction is required, which notice shall be consistent with the
requirements of Section 409A to avoid the imputation of any tax,
penalty or interest thereunder, then the Company shall reduce or
eliminate the Parachute Payments by first reducing or eliminating
any cash payments (with the payments to be made furthest in the
future being reduced first), then by reducing or eliminating
accelerated vesting of stock options or similar awards, and then by
reducing or eliminating any other remaining Parachute Payments;
provided, that no such reduction or elimination shall apply to any
non-qualified deferred compensation amounts (within the meaning of
Section 409A) to the extent such reduction or elimination would
accelerate or defer the timing of such payment in manner that does
not comply with Section 409A.

 

(b)          An
initial determination as to whether (x) any of the Parachute
Payments received by the Employee in connection with the occurrence
of a change in the ownership or control of the Company or in the
ownership of a substantial portion of the assets of the Company
shall be subject to the Excise Tax, and (y) the amount of any
reduction, if any, that may be required pursuant to the previous
paragraph, shall be made by an independent accounting firm selected
by the Company (the “Accounting Firm”) prior
to the consummation of such change in the ownership or effective
control of the Company or in the ownership of a substantial portion
of the assets of the Company. The Employee shall be furnished with
notice of all determinations made as to the Excise Tax payable with
respect to the Employee’s Parachute Payments, together with
the related calculations of the Accounting Firm, promptly after
such determinations and calculations have been received by the
Company.

 

(c)          For
purposes of this Section
5.17, (i) no portion of the Parachute Payments the receipt
or enjoyment of which the Employee shall have effectively waived in
writing prior to the date of payment of the Parachute Payments
shall be taken into account; (ii) no portion of the Parachute
Payments shall be taken into account which in the opinion of the
Accounting Firm does not constitute a “parachute
payment” within the meaning of Section 280G(b)(2) of the
Code; (iii) the Parachute Payments shall be reduced only to the
extent necessary so that the Parachute Payments (other than those
referred to in the immediately preceding clause (i) or (ii)) in
their entirety constitute reasonable compensation for services
actually rendered within the meaning of Section 280G(b)(4) of the
Code or are otherwise not subject to disallowance as deductions, in
the opinion of the auditor or tax counsel referred to in such
clause (ii); and (iv) the value of any non-cash benefit or any
deferred payment or benefit included in the Parachute Payments
shall be determined by the Company’s independent auditors
based on Sections 280G and 4999 of the Code and the regulations for
applying those sections of the Code, or on substantial authority
within the meaning of Section 6662 of the Code.

 

 

 

11

 

 

Section
5.18. Recoupment of
Erroneously Awarded Compensation. Any incentive-based or
other compensation paid to the Employee under this Agreement or any
other agreement or arrangement with the Company which is subject to
recovery under any law, government regulation, stock exchange
listing requirement or any clawback policy adopted by the Company
from time to time will be subject to the deductions and clawback as
may be required by such law, government regulation, stock exchange
listing requirement or clawback policy.  In
addition, if the Employee is or becomes an executive officer
subject to the incentive compensation repayment requirements of the
Dodd-Frank Wall Street Reform and Consumer Protection Act (the
“Dodd-Frank
Act”), then if required by the Dodd-Frank Act or any
of its regulations he will enter into an amendment to this
Agreement or a separate written agreement with the Company to
comply with the Dodd-Frank Act and any of its
regulations.

 

Section
5.19. Certain
Definitions. As used in this Agreement, “Change in Control” means
(x) a change in ownership of the Company under clause (i) below or
(y) a change in the ownership of a substantial portion of the
assets of the Company under clause (ii) below:

 

(i) Change in the Ownership of the
Company. A change in the ownership of the Company shall
occur on the date that any one person, or more than one person
acting as a group (as defined in clause (iii) below), acquires
ownership of capital stock of the Company that, together with
capital stock held by such person or group, constitutes more than
50 percent of the total fair market value or total voting power of
the capital stock of the Company. However, if any one person or
more than one person acting as a group, is considered to own more
than 50 percent of the total fair market value or total voting
power of the capital stock of the Company, the acquisition of
additional capital stock by the same person or persons shall not be
considered to be a change in the ownership of the Company. An
increase in the percentage of capital stock owned by any one
person, or persons acting as a group, as a result of a transaction
in which the Company acquires capital stock in the Company in
exchange for property will be treated as an acquisition of stock
for purposes of this paragraph.

 

(ii)  Change
in the Ownership of a Substantial Portion of the Company’s
Assets. A change in the ownership of a substantial portion
of the Company’s assets shall occur on the date that any one
person, or more than one person acting as a group (as defined in
clause (iii) below), acquires (or has acquired during the 12-month
period ending on the date of the most recent acquisition by such
person or persons) assets from the Company that have a total gross
fair market value equal to or more than 80 percent of the total
gross fair market value of all of the assets of the Company
immediately prior to such acquisition or acquisitions. For this
purpose, gross fair market value means the value of the assets of
the Company, or the value of the assets being disposed of,
determined without regard to any liabilities associated with such
assets. There is no Change in Control under this clause (ii) when
there is a transfer to an entity that is controlled by the
shareholders of the Company immediately after the transfer, as
provided below in this clause (ii). A transfer of assets by the
Company is not treated as a change in the ownership of such assets
if the assets are transferred to (a) a shareholder of the Company
(immediately before the asset transfer) in exchange for or with
respect to its capital stock, (b) an entity, 50 percent or more of
the total value or voting power of which is owned, directly or
indirectly, by the Company, (c) a person, or more than one person
acting as a group, that owns, directly or indirectly, 50 percent or
more of the total value or voting power of all the outstanding
capital stock of the Company, or (d) an entity, at least 50 percent
of the total value or voting power of which is owned, directly or
indirectly, by a person described in clause (ii)(c) of this
paragraph. For purposes of this clause (ii), a person's status is
determined immediately after the transfer of the
assets.

 

 

 

12

 

 

(iii)  Persons
Acting as a Group. For purposes of clauses (i) and (ii)
above, persons will not be considered to be acting as a group
solely because they purchase or own capital stock or purchase
assets of the Company at the same time. However, persons will be
considered to be acting as a group if they are owners of a
corporation that enters into a merger, consolidation, purchase or
acquisition of assets or capital stock, or similar business
transaction with the Company. If a person, including an entity,
owns stock in both corporations that enter into a merger,
consolidation, purchase or acquisition of assets or capital stock,
or similar transaction, such shareholder is considered to be acting
as a group with other shareholders in a corporation only with
respect to the ownership in that corporation before the transaction
giving rise to the change and not with respect to the ownership
interest in the other corporation. For purposes of this paragraph,
the term “corporation” shall have the meaning assigned
such term under Treasury Regulation section 1.280G-1,
Q&A-45.

 

(iv)  Each
of clauses (i) through (iii) above shall be construed and
interpreted consistent with the requirements of Section 409A and
any Treasury Regulations or other guidance issued
thereunder.

 

[Signature Page Follows]

 

13

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above
written.

 

COMPANY

 

ADGERO
BIOPHARMACEUTICALS

HOLDINGS,
INC.

 

By:___/s/ Frank
Pilkiewicz______________

Name:                       

Frank Pilkiewicz,
PhD

Title:                       

Chief Executive
Officer

 

 

EMPLOYEE

 

 

 

/s/ Felix
Garzon___________________________

Felix
Garzon

 

 

 

 

 

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]